阿维鲁单抗联合阿昔替尼治疗错配修复功能正常复发性或持续性子宫内膜癌的2期两阶段研究
在35例错配修复功能正常(MMRP)的复发性子宫内膜癌患者中开展单臂2期研究,评估阿维鲁单抗联合阿昔替尼的疗效与安全性。客观缓解率(ORR)为40%(95%CI 23.9%-57.9%),确认的ORR为25.7%(95%CI 12.5%-43.3%),6个月无进展生存率为55.8%,中位无进展生存期估计为7个月。联合方案安全性可接受,在MMRP复发性子宫内膜癌中显示出令人鼓舞的活性。
要点
- 35例MMRP复发性子宫内膜癌患者接受阿维鲁单抗联合阿昔替尼治疗,ORR为40%。
- 确认的ORR为25.7%,6个月PFS率为55.8%,中位PFS估计为7个月。
- 最常见≥3级治疗相关毒性为高血压(37.1%),5例(14.3%)因毒性停药。
核心结论
- 阿维鲁单抗联合阿昔替尼安全性可接受,在复发性MMRP子宫内膜癌中显示出令人鼓舞的活性。
研究设计与样本
- 研究者发起的单臂2期研究(NCT02912572),纳入35例接受方案治疗的MMRP复发性子宫内膜癌患者。
- 入选标准为任何组织学的复发性子宫内膜癌、MMRP、可测量病灶、既往治疗次数无上限且未接受过免疫检查点抑制剂治疗。
- 共同主要终点为客观缓解率(ORR)和6个月无进展生存率(PFS6),并进行了靶向二代测序和多重免疫荧光检测。
主要发现
- 14例客观缓解(ORR 40%,95%CI 23.9%-57.9%),包括1例确认的完全缓解、1例未确认的完全缓解、8例确认的部分缓解和4例未确认的部分缓解。
- 13例(37.1%)疾病稳定,6例(17.1%)疾病进展。
- 确认的ORR为25.7%(95%CI 12.5%-43.3%),中位缓解持续时间估计为13.8个月,6个月PFS率为55.8%,中位PFS估计为7个月。
- 最常见的≥3级治疗相关毒性为高血压(37.1%)、丙氨酸氨基转移酶升高(5.7%)和天冬氨酸氨基转移酶升高(5.7%);5例(14.3%)因毒性停止方案治疗。
- TP53突变肿瘤的ORR为48%,NSMP肿瘤的ORR为28.6%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Combinations of immune checkpoint inhibitors (ICIs) and antiangiogenic agents have demonstrated potent clinical activity across multiple tumor types. We hypothesized that the combination of axitinib, a highly potent inhibitor of VEGFR1-3, with the anti-PD-L1 antibody avelumab would be well tolerated and effective in the treatment of recurrent MMRP EC. METHODS: We conducted an investigator-initiated, single-arm phase 2 study of avelumab/axitinib in MMRP EC (NCT02912572). Eligible participants had recurrent EC of any histology that was MMRP, measurable disease, no upper limit of prior therapies and no prior ICI treatment. Co-primary endpoints were objective response rate (ORR) and progression-free survival rate at 6 months (PFS6). Targeted next-generation sequencing and multiplexed immunofluorescence were performed. RESULTS: Thirty-five patients initiated protocol therapy. There were 14 objective responses (ORR 40 %, 95 % CI 23.9 %-57.9 %), including 1 confirmed CR, 1 unconfirmed CR, 8 confirmed PRs, and 4 unconfirmed PRs. Thirteen patients (37.1 %) had stable disease (SD), and 6 (17.1 %) patients had progressive disease (PD). The confirmed objective response rate (ORR) was 25.7 % (95 % CI 12.5 % to 43.3 %), estimated median DOR was 13.8 months, PFS at 6 months was 55.8 %, and the estimated median PFS was 7 months. The most common G3+ treatment-related toxicities were hypertension (37.1 %), ALT increased (5.7 %) and AST increased (5.7 %); 5 (14.3 %) patients discontinued protocol therapy because of toxicity. Objective response rate was 48 % in TP53 mutated tumors and 28.6 % in NSMP tumors. CONCLUSIONS: Avelumab and axitinib had an acceptable safety profile and demonstrated encouraging activity in recurrent MMRP EC.
引用
- Lee EK, Xiong N, Krasner C, et al. Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer. Gynecol Oncol. 2025. PMID: 40393272. doi:10.1016/j.ygyno.2025.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。